Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIRE-12: Modified FOLFIRINOX vs FOLFOX in Small Bowel Adenocarcinoma
2025-524131-39-00Phase 3Authorised
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Oct 2026
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of irinotecan, oxaliplatin, fluorouracil and folinic acid in small bowel adenocarcinoma (SBA) (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Progression-free survival. Planned start Oct 2026; status: authorised.
02
Drugs
irinotecanoxaliplatinfluorouracilfolinic acid
03
Conditions
small bowel adenocarcinoma (SBA)
Beyond the preview
Go deeper on 2025-524131-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524131-39-00.